文献速递头颈外科

西妥昔单抗联合化疗治疗复发或转移性头颈鳞癌的印度回顾性分析

Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis.
PubMed 文献 · Head Neck · 2020-01-08

该研究回顾性分析229例接受姑息化疗的印度复发或转移性头颈鳞癌患者,其中联合西妥昔单抗组140例、单纯化疗组89例。联合组在缓解率、无进展生存期和总生存期上均优于单纯化疗组,且除皮肤反应外不良事件相似。

要点

  • 联合西妥昔单抗可提高缓解率、无进展生存期和总生存期
  • 联合组皮肤反应更常见,其余不良事件与单纯化疗相似
  • 体能状态好的患者持续用西妥昔单抗并更换化疗方案可延长总生存期

核心结论

  • 在印度复发或转移性头颈鳞癌患者中,化疗联合西妥昔单抗可改善客观缓解率、无进展生存期和总生存期,且耐受性良好。

研究设计与样本

  • 回顾性分析229例复发或转移性头颈鳞癌患者,联合西妥昔单抗加化疗组140例,单纯化疗组89例,评估缓解率、无进展生存期、总生存期和安全性。

主要发现

  • 联合组对比单纯化疗组:缓解率77.1% vs 44.9%(P = .0001),无进展生存期8.1 vs 6.1个月(P = .039),总生存期11.8 vs 8.0个月(P = .002)。
  • 体能状态好的患者中,持续使用西妥昔单抗并更换化疗组合(二线及以上)使总生存期翻倍(13.5 vs 6.1个月,P = .001)。
  • 除皮肤反应在联合组更多见外(P = .001),两组不良事件相似。

关键数值与推荐

  • 缓解率:联合组77.1%,单纯化疗组44.9%(P = .0001)。
  • 无进展生存期:联合组8.1个月,单纯化疗组6.1个月(P = .039)。
  • 总生存期:联合组11.8个月,单纯化疗组8.0个月(P = .002)。
  • 二线及以上持续西妥昔单抗并更换化疗:总生存期13.5 vs 6.1个月(P = .001)。

临床怎么用

  • 对体能状态适合的复发或转移性头颈鳞癌患者,可考虑化疗联合西妥昔单抗以改善缓解率和生存。
  • 治疗中需关注西妥昔单抗相关皮肤反应。
  • 体能状态好的患者在后线治疗中持续使用西妥昔单抗并更换化疗组合可能获益。

局限性

  • 为单中心回顾性分析,存在选择偏倚等回顾性研究固有局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report our experience with Indian patients who received palliative chemotherapy with/without cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: Data from 229 R/M SCCHN patients treated with cetuximab and chemotherapy (n = 140) or chemotherapy alone (n = 89) were retrospectively analyzed for response rate (RR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Patients receiving cetuximab with chemotherapy demonstrated significant increase in RR (77.1% vs 44.9%, P = .0001), PFS (8.1 vs 6.1 months, P = .039), and OS (11.8 vs 8.0 months, P = .002) compared with patients receiving chemotherapy alone. Continuing cetuximab and changing chemotherapy combination (second line and beyond) in fit patients doubled OS (13.5 vs 6.1 months, P = .001). Adverse effects, except skin reactions (more in the cetuximab with chemotherapy group; P = .001), were similar in both groups. CONCLUSION: Adding cetuximab to chemotherapy improved ORR, PFS, and OS in Indian R/M SCCHN patients, and cetuximab was well tolerated.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Bahl A, Bhatia K, Choudhary P, et al. Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis. Head Neck. 2020. PMID: 31916340. doi:10.1002/hed.26070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。